Arbutus Historical Income Statement
| ABUS Stock | USD 3.21 0.01 0.31% |
Historical analysis of Arbutus Biopharma income statement accounts such as Interest Expense of 701.5 K, Selling General Administrative of 27.1 M or Total Revenue of 12.7 M can show how well Arbutus Biopharma Corp performed in making a profits. Evaluating Arbutus Biopharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Arbutus Biopharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Arbutus Biopharma Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Arbutus Biopharma Corp is a good buy for the upcoming year.
Arbutus |
About Arbutus Income Statement Analysis
Arbutus Biopharma Corp Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Arbutus Biopharma shareholders. The income statement also shows Arbutus investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Arbutus Biopharma Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Arbutus Biopharma Corp generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Arbutus Biopharma Corp. It is also known as Arbutus Biopharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Arbutus Biopharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Arbutus Biopharma Corp current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arbutus Biopharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. At this time, Arbutus Biopharma's Reconciled Depreciation is comparatively stable compared to the past year.
Arbutus Biopharma income statement Correlations
Click cells to compare fundamentals
Arbutus Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Arbutus Biopharma income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Depreciation And Amortization | 2.0M | 1.8M | 1.4M | 1.4M | 1.3M | 1.4M | |
| Interest Expense | 4.0M | 2.9M | 1.7M | 459K | 527.9K | 701.5K | |
| Selling General Administrative | 14.7M | 17.1M | 17.8M | 22.5M | 25.8M | 27.1M | |
| Total Revenue | 6.9M | 11.0M | 39.0M | 18.1M | 20.9M | 12.7M | |
| Gross Profit | (40.6M) | 9.2M | 37.6M | (55.6M) | (50.0M) | (47.5M) | |
| Other Operating Expenses | 64.2M | 82.6M | 102.2M | 96.2M | 110.7M | 116.2M | |
| Operating Income | (57.8M) | (73.5M) | (65.5M) | (78.1M) | (70.3M) | (73.8M) | |
| Ebit | (59.8M) | (73.4M) | (63.3M) | (72.4M) | (65.2M) | (61.9M) | |
| Research Development | 47.5M | 65.5M | 84.4M | 73.7M | 66.3M | 63.0M | |
| Ebitda | (57.8M) | (71.6M) | (61.9M) | (71.0M) | (63.9M) | (60.7M) | |
| Total Operating Expenses | 64.2M | 82.6M | 102.2M | 96.2M | 110.7M | 116.2M | |
| Net Income | (65.2M) | (77.4M) | (69.5M) | (72.8M) | (65.6M) | (68.8M) | |
| Net Income From Continuing Ops | (63.7M) | (76.2M) | (69.5M) | (75.5M) | (67.9M) | (71.3M) | |
| Cost Of Revenue | 47.5M | 1.8M | 1.4M | 73.7M | 84.8M | 89.0M | |
| Income Before Tax | (63.7M) | (76.2M) | (65.0M) | (72.8M) | (65.6M) | (68.8M) | |
| Total Other Income Expense Net | (5.9M) | (2.7M) | 444K | 5.3M | 4.7M | 5.0M | |
| Net Income Applicable To Common Shares | (329.7M) | (75.9M) | (88.4M) | (69.5M) | (62.5M) | (65.6M) | |
| Income Tax Expense | 1.5M | 1.1M | 4.4M | (1.0) | (0.9) | (0.94) | |
| Non Operating Income Net Other | 24.8M | (1.9M) | 132K | 2.2M | 2.5M | 2.4M | |
| Interest Income | 741K | 127K | 2.2M | 5.2M | 4.6M | 3.7M | |
| Net Interest Income | (3.3M) | (2.7M) | 466K | 4.4M | 4.0M | 4.2M | |
| Preferred Stock And Other Adjustments | 10.1M | 11.1M | 12.1M | 12.1M | 14.0M | 10.2M | |
| Reconciled Depreciation | 2.0M | 1.8M | 1.4M | 1.4M | 1.2M | 1.5M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.